Vertex Pharmaceuticals Incorpor with price, financials, news flow, and insider context in one page.
Vertex Pharmaceuticals Incorpor is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where VRTX sits inside Healthcare and Biotechnology, and the key financial markers that matter before moving into a fuller research workflow.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
This page is structured for research context, not a trade call. It gives you a clean read on where VRTX sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 2.99B | 1.03B | 1.29B |
| Q4 2025 | 3.19B | 1.19B | 348.6M |
| Q3 2025 | 3.08B | 1.08B | 1.14B |
| Q2 2025 | 2.96B | 1.03B | 927.4M |
The attacks come as the United States and Iran are supposed to be engaging in a 60-day ceasefire as they attempt to work toward a resolution.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Vertex Pharmaceuticals Incorpor (VRTX) — questions investors ask
What is the current stock price of Vertex Pharmaceuticals Incorpor (VRTX)?
Vertex Pharmaceuticals Incorpor (VRTX) is trading at $491.34, up 2.32% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Vertex Pharmaceuticals Incorpor's market capitalization?
Vertex Pharmaceuticals Incorpor has a market capitalization of about 124.7B, derived from the latest share price and shares outstanding.
When is Vertex Pharmaceuticals Incorpor's next earnings date?
Vertex Pharmaceuticals Incorpor is next expected to report earnings on Aug 3, 2026. The VRTX earnings page tracks the estimate and reporting history.
What is Vertex Pharmaceuticals Incorpor's P/E ratio?
Vertex Pharmaceuticals Incorpor trades at a forward price-to-earnings ratio of 22.88 — one measure of how the market is pricing its future earnings.
What is VRTX's 52-week trading range?
Over the past 52 weeks, VRTX has traded between $362.50 and $507.92.
What sector is Vertex Pharmaceuticals Incorpor in?
Vertex Pharmaceuticals Incorpor operates in the Healthcare sector, within the Biotechnology industry.
What is the analyst price target for VRTX?
The mean analyst price target for VRTX is $548.69, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This VRTX page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.